Christopher Posner
2023
In 2023, Christopher Posner earned a total compensation of $2.9M as President and Chief Executive Officer at Cara Therapeutics, a 16% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $414,960 |
|---|---|
| Option Awards | $1,769,000 |
| Salary | $728,000 |
| Other | $10,509 |
| Total | $2,922,469 |
Posner received $1.8M in option awards, accounting for 61% of the total pay in 2023.
Posner also received $415K in non-equity incentive plan, $728K in salary and $10.5K in other compensation.
Rankings
In 2023, Christopher Posner's compensation ranked 322nd out of 2,983 executives tracked by ExecPay. In other words, Posner earned more than 89.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 322 out of 2,983 | 89th |
Division Manufacturing | 179 out of 1,637 | 89th |
Major group Chemicals And Allied Products | 122 out of 906 | 87th |
Industry group Drugs | 119 out of 869 | 86th |
Industry Pharmaceutical Preparations | 76 out of 627 | 88th |
Source: SEC filing on April 22, 2024.
Posner's colleagues
We found two more compensation records of executives who worked with Christopher Posner at Cara Therapeutics in 2023.